MX341015B - Forma de dosificacion de liberacion extendida. - Google Patents

Forma de dosificacion de liberacion extendida.

Info

Publication number
MX341015B
MX341015B MX2009008197A MX2009008197A MX341015B MX 341015 B MX341015 B MX 341015B MX 2009008197 A MX2009008197 A MX 2009008197A MX 2009008197 A MX2009008197 A MX 2009008197A MX 341015 B MX341015 B MX 341015B
Authority
MX
Mexico
Prior art keywords
bead
extended
release dosage
dosage form
inner core
Prior art date
Application number
MX2009008197A
Other languages
English (en)
Spanish (es)
Other versions
MX2009008197A (es
Inventor
Pavan Bhat
Sarat C Chattaraj
Andrew A Shaw
Original Assignee
Mylan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Pharmaceuticals Inc filed Critical Mylan Pharmaceuticals Inc
Publication of MX2009008197A publication Critical patent/MX2009008197A/es
Publication of MX341015B publication Critical patent/MX341015B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2009008197A 2007-02-01 2008-01-24 Forma de dosificacion de liberacion extendida. MX341015B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/701,178 US20080187579A1 (en) 2007-02-01 2007-02-01 Extended-release dosage form
PCT/US2008/000926 WO2008094440A1 (en) 2007-02-01 2008-01-24 Extended-release dosage form

Publications (2)

Publication Number Publication Date
MX2009008197A MX2009008197A (es) 2009-10-28
MX341015B true MX341015B (es) 2016-08-04

Family

ID=39496215

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008197A MX341015B (es) 2007-02-01 2008-01-24 Forma de dosificacion de liberacion extendida.

Country Status (11)

Country Link
US (3) US20080187579A1 (enExample)
EP (1) EP2114382A1 (enExample)
JP (2) JP5868571B2 (enExample)
KR (1) KR20090109117A (enExample)
CN (1) CN101646422A (enExample)
AU (1) AU2008211318B2 (enExample)
BR (1) BRPI0807001A2 (enExample)
CA (1) CA2676650C (enExample)
MX (1) MX341015B (enExample)
NZ (1) NZ578656A (enExample)
WO (1) WO2008094440A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
JP2013504562A (ja) * 2009-09-17 2013-02-07 カディラ・ヘルスケア・リミテッド アルコールで誘発される用量ダンピングを低減するための医薬組成物
ES2698611T3 (es) 2012-07-12 2019-02-05 SpecGx LLC Composiciones farmacéuticas disuasorias del abuso y de liberación prolongada
CN104587472B (zh) * 2014-12-31 2017-12-15 广东国方医药科技有限公司 一种含纳米SiO2的包衣剂及其制备方法
WO2017058869A1 (en) 2015-09-29 2017-04-06 Acorda Therapeutics, Inc. Sustained release compositions of 4-aminopyridine
US20170119680A1 (en) * 2015-10-30 2017-05-04 R.P. Scherer Technologies, Llc Extended release film-coated capsules
KR20180108814A (ko) * 2016-02-11 2018-10-04 바이오젠 엠에이 인코포레이티드 다이메틸 퓨마레이트를 포함하는 약제학적 비드 제형
US10406336B2 (en) 2016-08-03 2019-09-10 Neil S. Davey Adjustable rate drug delivery implantable device
CN114288273B (zh) * 2022-02-11 2022-10-18 桂林华信制药有限公司 一种盐酸文拉法辛缓释胶囊及其生产工艺
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US4587118A (en) * 1981-07-15 1986-05-06 Key Pharmaceuticals, Inc. Dry sustained release theophylline oral formulation
US4556678A (en) * 1982-06-24 1985-12-03 Key Pharmaceuticals, Inc. Sustained release propranolol tablet
PH18946A (en) * 1983-04-21 1985-11-14 Elan Corp Plc Controlled absorption pharmaceutical composition
EP0164669B1 (de) * 1984-06-13 1991-01-23 Röhm Gmbh Verfahren zum Überziehen von Arzneiformen
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5683719A (en) * 1990-11-22 1997-11-04 British Technology Group Limited Controlled release compositions
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
DE19504832A1 (de) * 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
IT1289160B1 (it) * 1997-01-08 1998-09-29 Jagotec Ag Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di
WO2000018500A1 (de) * 1998-09-24 2000-04-06 Glatt Systemtechnik Dresden Gmbh Einrichtung zur herstellung eines schüttfähigen produktes und verfahren zur anwendung der einrichtung
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
US9358214B2 (en) * 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US7401157B2 (en) * 2002-07-30 2008-07-15 Brocade Communications Systems, Inc. Combining separate infiniband subnets into virtual subnets
US6780003B2 (en) * 2002-08-02 2004-08-24 Mold-Masters Limited Removable heater for a hot runner nozzle
GB0222612D0 (en) * 2002-09-30 2002-11-06 Univ Gent Controlled delivery system for bioactive substances
US9107804B2 (en) * 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride

Also Published As

Publication number Publication date
EP2114382A1 (en) 2009-11-11
JP5868571B2 (ja) 2016-02-24
WO2008094440A1 (en) 2008-08-07
JP5876896B2 (ja) 2016-03-02
AU2008211318B2 (en) 2013-08-01
US20110123613A1 (en) 2011-05-26
US20080187579A1 (en) 2008-08-07
CN101646422A (zh) 2010-02-10
MX2009008197A (es) 2009-10-28
CA2676650A1 (en) 2008-08-07
CA2676650C (en) 2014-09-16
AU2008211318A1 (en) 2008-08-07
BRPI0807001A2 (pt) 2014-04-15
US20170049724A1 (en) 2017-02-23
JP2014208655A (ja) 2014-11-06
JP2010518002A (ja) 2010-05-27
KR20090109117A (ko) 2009-10-19
NZ578656A (en) 2011-06-30

Similar Documents

Publication Publication Date Title
MX341015B (es) Forma de dosificacion de liberacion extendida.
WO2008022932A3 (en) Controlled release system and method for manufacturing the same
WO2007103557A3 (en) Coating capsules with active pharmaceutical ingredients
WO2009117130A3 (en) Extended release forumulation containing a wax
EP3988089A4 (en) LIPID NANOPARTICLES FOR IN VIVO DRUG DELIVERY, AND ASSOCIATED USES
WO2008132712A3 (en) Combination pharmaceutical compositions
MX2011006578A (es) Formulaciones farmaceuticas de liberacion prolongada.
WO2004062577A3 (en) Two or more enteric materials to regulate drug release
WO2007036952A3 (en) Novel sustained release dosage form
MY149623A (en) Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
PH12013500289A1 (en) Nalbuphine-based formulations and uses thereof
WO2007144169A3 (en) Entacapone-derivatives
WO2009106824A3 (en) Pharmaceutical formulations with a taste masking coating
IL179012A (en) A drug containing cetirizine for the treatment of nasal inflammation, a process for its preparation and use
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same
WO2009028598A1 (ja) 徐放性製剤及びその製造方法
WO2006123364A3 (en) Oral drug delivery system providing a coating comprising both a cellulose and a methacrylic acid derivative
TW200602090A (en) Antibiotic-based pharmaceutical formulation in microcapsular form
WO2008004100A3 (en) Therapeutic compounds
TN2010000302A1 (en) Estradiol-containing drug delivery system
IN2014CN02343A (en) Oral formulations containing hyaluronic acid for sustained drug release
GEP20115158B (en) Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction
WO2011159491A8 (en) Controlled release levetiracetam formulations
WO2008029351A3 (en) A modified release formulation comprising amoxicillin and clavulanate

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration